Jobs news round-up
Paul Smaglik
Friday, 10 October 2008 18:39 UTC
Here’s a smattering of science career-related news from around the web:
Every year the Times Higher Education Supplement ranks the top 200 universites in the world. Administrators tend to dismiss such lists—unless of course their university lands at the top. The UK’s slippage this year is causing some consternation
The Wall Street Journal “Career Journal” has an interesting piece about mentoring.
GSK’s cuts of 850 R&D jobs at the beginning of this month may be just the beginning. More big pharma companies are looking outside the company to fill their pipelines.
This report on US state biotech initiaitves has been out for awhile, but somehow, I just noticed it. It could be a good resource for people looking to move jobs in biotech.
Physicists are mourning the impending death of basic research at Bell Labs, once considered a paragon of industry sponsoring pure science without an eye toward obvious applications. Here’s another elegy to the passing of the New Jersey giant.
Here’s an interesting physics postdoc tale.
And a solid interview with Abou Gharbia, senior vice presdidet at Wyeth, concerning navigating a career within pharma
Finally, here’s a blog post about negotiating a better salary when you have a history of working at below-market pay.
Please suggest any other interesting headlines, reports, blog posts, etc. so I can aggregate them into the mix. As always, please let us know if, whether and how any of this stuff affects you.
Cheers,
PS
-
Replies
-
“Finally, here’s a blog post about negotiating a better salary when you have a history of working at below-market pay.”
Given the current economic climate, it wouldn’t be a good idea to bring it up with your boss, they might just add you to that ‘job cut’ list! -
The global economic meltdown—characterized by tanking stock market indexes and frozen bank-to-bank lending—is affecting the scientific job market, both in academia and industry. US state universities are seeing their cash reserves dry up, while private institutions are facing endowment decreases, according to the Wall Street Journal.
Meanwhile, the Royal Society of Chemistry’s Commercial Chemist reflects the industrial downtown, with a list of restructurings, closures and realignments in the chemistry and pharma world.
The Royal Society’s Chemistry World points out one possible bright spot; China may actually up its R&D investment.
That investment, if it comes, could be indicative of a shifting global workforce. Business types are already looking toward the Mideast and Asia for their next jobs, according to the WSJ
Would-be science hubs in China, Singtapore, Dubai and beyond may begin looking more attractive to R&D workers from the West, if the economy doesn’t soon right itself; for those considering switching countries or continents, the American Chemical Society has a blog about working across cultural borders.
-
